Podcasts & Media
CFSRE staff and NPS Discovery collaborators are involved in highly engaging podcasts across various platforms and topic areas. These podcasts are a great way to hear from our scientists and learn more about our program, projects, and initiatives! If you are interested in having our scientists join your podcast, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..
April 20, 2023
The Toxpod - NPS Update, April 2023
Keeping up to date with New Psychoactive Substances is hard! We've assembled a crack team of experts to help us do just that: Michael Evans-Brown from EMCDDA, Conor Crean from UNODC, and Alex Krotulski from CFSRE.
These updates will be a regular part of our podcast schedule, letting you know about recent developments in NPS markets, detection and harms. In this episode we discuss an increasing trend of xylazine in fentanyl supplies, the recent scheduling of some NPS by the United Nations, and the emergence of semi-synthetic cannabinoids including HHC.
LISTEN NOW
These updates will be a regular part of our podcast schedule, letting you know about recent developments in NPS markets, detection and harms. In this episode we discuss an increasing trend of xylazine in fentanyl supplies, the recent scheduling of some NPS by the United Nations, and the emergence of semi-synthetic cannabinoids including HHC.
LISTEN NOW
May 16, 2022
Benzo Dope and Tranq: The Next Wave of the Overdose Crisis
More than 100,000 Americans died of a drug overdose in 2021, the worst year on record. The newest wave of the overdose crisis involves man-made chemicals, including animal tranquilizers, that are being combined with fentanyl to make street drugs that are deadlier and more addictive.
With access to an undisguised fentanyl dealer, Beyond Fentanyl looks at how drugs like “benzo dope” and “tranq” are ravaging North American communities and how U.S. policy affected the latest flood of synthetic street drugs.
Watch Now
With access to an undisguised fentanyl dealer, Beyond Fentanyl looks at how drugs like “benzo dope” and “tranq” are ravaging North American communities and how U.S. policy affected the latest flood of synthetic street drugs.
Watch Now
April 7, 2022
NPS Update
Keeping up to date with New Psychoactive Substances is hard! We've assembled a crack team of experts to help us do just that: Michael Evans-Brown from EMCDDA, Conor Crean from UNODC, and Alex Krotulski CFSRE and NPS Discovery.
These updates will be a regular part of our podcast schedule, letting you know about recent developments in NPS markets, detection and harms. In this episode we discuss cathinones, the recent contamination of synthetic cannabinoids with brodifacoum, and the future of psychedelics.
LISTEN NOW
These updates will be a regular part of our podcast schedule, letting you know about recent developments in NPS markets, detection and harms. In this episode we discuss cathinones, the recent contamination of synthetic cannabinoids with brodifacoum, and the future of psychedelics.
LISTEN NOW
September 27, 2021
NPS Update
Keeping up to date with New Psychoactive Substances is hard! We've assembled a crack team of experts to help us do just that: Michael Evans-Brown from EMCDDA, Conor Crean from UNODC, and Alex Krotulski CFSRE and NPS Discovery.
Listen Now
Listen Now
June 15, 2021
New Psychoactive Substances with Alex Krotulski
“New Psychoactive Substances with Alex Krotulski” comes from the ToxPod with Tim Scott and Peter Stockham discussing NPS and expanding world of NPS Discovery.
Listen Now
Listen Now
April 23, 2021
Street Sampling Synthetics, from Carfentanil to Xylazine with Alex Krotulski
“Street Sampling Synthetics, from Carfentanil to Xylazine with Alex Krotulski” comes from Narcotica focusing on drug trends, combinations, and much more.
Listen Now
Listen Now
February 5, 2021
Just the Importance of Identifying Emerging Drug Threats
CFSRE’s Mandi Mohr and Alex Krotulski comes from RTI and NIJ’s Forensic Technology Center of Excellence [FTCoE, Award 2016-MU-BX-K110] to discuss the analytical and interpretative challenges associated with emerging drug threats and NPS.
